Analysts Offer Insights on Healthcare Companies: Merus (MRUS), Vanda (VNDA) and Travere Therapeutics (TVTX)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Merus (MRUS – Research Report), Vanda (VNDA – Research Report) and Travere Therapeutics (TVTX – Research Report).

Elevate Your Investing Strategy:

• Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Merus (MRUS)

In a report released today, John Newman from Canaccord Genuity maintained a Hold rating on Merus, with a price target of $97.00. The company’s shares closed last Monday at $94.88.

According to TipRanks.com, Newman is a 1-star analyst with an average return of -1.6% and a 36.6% success rate. Newman covers the Healthcare sector, focusing on stocks such as Allogene Therapeutics, Marker Therapeutics, and Candel Therapeutics. ;'>

Currently, the analyst consensus on Merus is a Hold with an average price target of $97.71, representing a 3.0% upside. In a report issued on October 24, Needham also maintained a Hold rating on the stock.

See the top stocks recommended by analysts >>

Vanda (VNDA)

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Vanda today and set a price target of $20.00. The company’s shares closed last Monday at $4.40.

According to TipRanks.com, Selvaraju is a 5-star analyst with an average return of 23.3% and a 51.4% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Santhera Pharmaceuticals Holding, Reviva Pharmaceuticals Holdings, and MoonLake Immunotherapeutics. ;'>

Currently, the analyst consensus on Vanda is a Moderate Buy with an average price target of $20.00.

Travere Therapeutics (TVTX)

In a report released today, Edward Nash from Canaccord Genuity maintained a Buy rating on Travere Therapeutics, with a price target of $47.00. The company’s shares closed last Monday at $34.43.

According to TipRanks.com, Nash is a 5-star analyst with an average return of 23.0% and a 50.8% success rate. Nash covers the Healthcare sector, focusing on stocks such as Sagimet Biosciences, Inc. Class A, Rani Therapeutics Holdings, and Madrigal Pharmaceuticals. ;'>

Travere Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $37.38, which is an 8.1% upside from current levels. In a report issued on October 30, TD Cowen also maintained a Buy rating on the stock with a $40.00 price target.

Read More on MRUS:

Disclaimer & DisclosureReport an Issue

• Cautious Hold Rating on Merus Amid Genmab Acquisition Uncertainty and Promising Pipeline
• Merus NV’s Financial Stability at Risk Due to Unproven ADClonics Technology and Supply Chain Vulnerabilities
• Merus NV Faces Uncertainty and Risks Amid Genmab A/S Transaction Delays
• Merus NV (MRUS) Q3 Earnings Cheat Sheet
• Merus N.V.’s Zenocutuzumab Study Termination: Market Implications